Syndivia and BFCL publish review of Antibody–Oligonucleotide Conjugates (AOC) as therapeutic, imaging, and detection agents

Syndivia and Biofunctional Chemistry Laboratory announce publication of a review titled “Antibody–Oligonucleotide Conjugates as Therapeutic, Imaging, and Detection Agents” in Bioconjugate Chemistry. The review gives a comprehensive overview of the main applications of antibody-oligonucleotide conjugates (AOC) as well as major synthetic approaches used for their preparation. The review emphasized the importance of the development of novel methods for efficient and reliable generation of AOC, in order to advance their new applications.

https://pubs.acs.org/doi/10.1021/acs.bioconjchem.9b00306

Syndivia presenting at MedFIT 2018

Syndivia’s CEO, Dr Oleksanr Koniev, will be giving a talk at MedFIT 2018, Strasbourg, France, on Wednesday, 27th June 2018. MedFIT is the leading European partnering event dedicated to innovation partnerships and the main marketplace for early-stage investment in the fields of medical technology, diagnostic and digital health.

logo_medfit.jpg

Syndivia wins the France Tech Transfer Invest Award

PARIS, France, February 2, 2017 -- Syndivia wins the France Tech Transfer Invest Award during a Tech Tour event that took place in Paris on 1-2 February 2017. The event is a collaboration between the SATT, Tech Tour, Bpifrance and its EuroQuity platform and aims to efficiently and effectively support French tech companies to meet and engage with international investors and corporate partners.
For more information on the event visit: http://techtour.com/events/view.aspx?events_pages_id=7749

showlogo-aspx_orig.png

OGD2 Pharma and Syndivia launch collaboration to develop an ADC targeting the O-acetyl-GD2 cancer antigen

NANTES, France, Sept. 6, 2016 (GLOBE NEWSWIRE) -- OGD2 Pharma SAS, a biotechnology company developing innovative anti-cancer therapies targeting the O-acetylated form of the GD2 ganglioside (OAcGD2), today announces a collaboration with Syndivia SAS, a biotechnology company that provides best-in-class bioconjugation technologies for the development of Antibody-Drug Conjugates (ADC).

Full press release available at: http://globenewswire.com/news-release/2016/09/06/869521/10164974/en/OGD2-Pharma-and-Syndivia-launch-collaboration-to-develop-an-ADC-targeting-the-O-acetyl-GD2-cancer-antigen.html